Dac-13-2005 11:08

PHILADELPHIA

ATLANTA

CHARLOTTE

CHERRY HILL

CHICAGO

LAS VEGAS

LOS ANGELES

LONDON

DALLA5 DENVER From-COZEN O'CONNOR

215-665-2013

T-736 P.001/007 F-685

RECEIVED CENTRAL FAX CENTER FRANCISCO

NEWARK NEW YORK SAN DIEGO

SEATTLE

DEC 1 3 2005 WASHINGTON, DC

WEST CONSHOHOCKEN WICHITA WILMINGTON

A PROFESSIONAL CORPORATION

1900 MARKET STREET PHILADELPHIA, PA 19103-3508 215.665.2000 800.523.2900 215.665.2013 FAX www.cozen.com

Ser. No.: 10/747,702

Filing Date: December 30, 2003

Docket No. ASZN0039-101

Matter No.: 178061

Title: Novel G Protein-Coupled Receptor

Pages to Follow: 6

Sender's Name: Paul K. Legaard

Date: December 13, 2005

RECIPIENT(S)	COMPANY/FIRM	FAX	
Art Unit 1645	USPTO	(571) 273-8300	

MESSAGE: OFFICIAL FAX

PLEASE DELIVER TO ART UNIT 1645 ATTACHED IS:

- Transmittal Form (1 page) 1.
- Copy of Notice to Comply (2 pages) 2.
- Response to Notice to Comply (2 pages) 3.
- Copy of stamped Return Postcard (1 page) 4.

IF YOU DO NOT RECEIVE ALL PAGES, PLEASE CALL 215.665.2000 or 800.523.2900 IMMEDIATELY.

THIS TRANSMISSION IS ALSO BEING SENT VIA:

- Regular Mail
- Certified Mail
- _ Hand Delivery
- Overnight Mail
 Federal Express

NOTICE

The information contained in this transmission is privileged and confidential. It is intended for the use of the individual or entity named above. If the render of this message is not the intended addresses, the reader is bereby notified that any consideration, dissemination or duplication of this communication is strictly prohibited. If the addresses has received this communication in error, please return this transmission to us at the above address by mail. We will reimburse you for postage. In addition, if this communication was received in the U.S., please notify us immediately by phoning and asking for the Fax Center.

From-COZEN O'CONNOR

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM		Application Number	•	10/747,702			
		Filing Date		December 30, 2003			
		First Named Invent	or	Sultan Ahmad			
		Art Unit		1645			
(to be used for all correspondence after initial filing)		Examiner Name		Not Yet Determined			
Total Number of Pages in This Submission		Attorney Docket Nu	mber	ASZN0039-101 (A1807-2P US)			
	ENCLO	SURES (check all that	apply)				
Fee Transmittal Form		Drawing(s)			wance Communication to TC		
Fee Attached	Licensing	☐ Licensing-related Papers		Appeal Communication to Board			
Amendment / Reply	Petition				of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Briof, Reply Brief)		
After Final	Petition to Convert to a Provisional Application			Proprietary Information			
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address			Status Letter			
Extension of Time Request	Terminal Disclaimer			Other Enclosure(s) (please identity below):			
Express Abandonment Request	Request for Refund CD, Number of CD(s)			Copy of Notice to Comply Response to Notice to Comply Copy of stamped Return Postcard indicating receipt of application containing			
Information Disclosure Statement	☐ Landscape Table on CD Sequence Listing that was filed December 30, 2003				sting that was filed on		
Certified Copy of Priority Document(s)	Remarks						
Reply to Missing Parts/ Incomplete Application	i						
Reply to Missing Parts under 37 CFR1.52 or 1.53							
SIG	NATURE OF	APPLICANT, ATTOR	RNEY, OF	AGENT			
Firm	Cozen O'Connor						
Signature	Part & forme						
Printed Name	Paul K Legaard						
Date		Reg. No. 38,534					
		ATE OF TRANSMISS					
I hereby certify that this corresponde Service with sufficient postage as talexandria, VA 22313-1450 on the da	irst class mall	in an envelope address	ne USPTO ssed to: C	or deposited ommissioner	with the United States Posts for Patents, P.O. Box 1450		
Signature	0/1	y : P					
Typed or printed name Paul K.	egaard			Date	December 13, 2005		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time witi vary depending upon the includingsia case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and amount of time you require to complete the form, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1480, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX GENTER

DOCKET NO.: ASZN0039-101 (A1807-2P US)

DEC 13 2005 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ahmad, Banville, Fortin, Lembo, O'Donnell, and Shen

Serial No.: 10/747,702

Group Art Unit: 1645

Filed: December 30, 2003

Examiner: Not Yet Determined

Title: Novel G Protein-Coupled Receptor

Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office to facsimile number (571) 273-8300 on the date shown below.

On 13 December 2005

Paul K. Legaard, Reg. No. 38,534

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

RESPONSE TO THE NOTICE TO COMPLY

The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures (hereinafter, the "Notice To Comply") mistakenly asserts that the application does not contain a "Sequence Listing" pursuant to 37 CFR §1.821(c). Applicants respectfully request reconsideration.

The application as filed on December 30, 2003 was filed as a continuation of U.S. Serial No. 09/254,227 which was filed on March 3, 1999, which in turn was the National Phase filing of PCT International Application No. PCT/SE98/02348, which was filed December 16, 1998. The present application was filed WITH a Sequence Listing on pages 25-61 of the specification. A copy of the stamped Return Card indicating receipt of pages 1-62 of the application as filed (of which pages 25-61 contain the Sequence Listing) is provided herewith. The present Notice To

DOCKET NO.: ASZN0039-101 (A1807-2P US)

PATENT

Comply fails to recognize that an initial paper copy of the Sequence Listing was, in fact, filed with the original application.

Applicants respectfully submit that the present response is complete and that the application is ready for examination. An early notice of the same is earnestly solicited. The Examiner is invited to contact Applicants' undersigned representative at (215) 665-6914 if there are any questions regarding Applicants' Sequence Listing.

Respectfully submitted,

Paul K. Legaard, Ph.D.

Registration No. 38,534

Date: 13 December 2005

COZEN O'CONNOR, P.C. 1900 Market Street Philadelphia, PA 19103-3508 Telephone: (215) 665-6914 Facsimile: (215) 701-2141

-2-



<u> Inited States Patent alid Trademark Office</u>

UNITED STATES DEPARTMENT OF COMMERCIA United States Patent and Trademark Office Admired Commissional For Patent'S LO. Bet (45) Admired Lyuria 22013-1439

APPLICATION NUMBER

FILING OR : 71 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/747,702

12/30 2003

Sultan Ahmad

7567/80958

Michael A. Sanzo Fitch, Even, Tabin & Flannery Suite 401L 1801 K Street, N.W. Washington, DC 20006-1201

OCT:1 7 2005

FETF. D.C.

CONFIRMATION NO. 2881 FORMALITIES LETTER

Date Mailed: 10/14/2005

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Filing Date Granted

Applicant is given TWO MONTHS FROM "HE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an a mendment specifically directing its entry into the application and a statement that the content of the : equence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, size the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

To Download Patentin Software, /isit http://www.uspto.gov/web/patents/software.htm For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, c.ill (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-8845 between the hours of 6 a.m. and 12 midnight, Monday through Friday,
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Repties should be mailed to:

Mail St up Missing Parts

Commissioner for Patents

P.O. Bux 1450

Alexan Iria VA 22313-1450

A copy of this notice MUST be returned with the reply.

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382
PART I - ATTORNEY/APPLICANT COPY

215-665-2013

RECEIPT FROM USPTO FOR INDICATED ITEMS

Appln, No.:

TO BE ASSIGNED

Attorney:

M. Sanzo

Filed:

Dec-13-2005 11:10

HEREWITH

Date:

TOO I Lacarch Commeil of Canada filed in the parent

December 30, 2003

Inventor(s):

AHMAD, ET AL

Atty, Dkt.:

7567/80958

NOVEL G PROTEIN-COUPLED RECEPTOR

WHEN RECEIPT STAMP IS PLACED HEREON, THE USPTO ACKNOWLEDGES RECEIPT OF

THE FOLLOWING DOCUMENTS: OUR COVER LETTER ENCLOSING:

A copy of application no. 09/254, 227, as filed in the U.S. Preent and Trademark Office on March 3, 1999, comprising: a title page naming Shon Shi-Haiang, Sultan Ahmad, Yves Fortin, Denis Banville, Dajan Odonnell and Paola Lembo as inventors (wnumbered),

62 pages of specification (numbered as pages 1-62), 5 pages of claims (numbered as pages 63-67), a one page abstract (numbered as page 68), and 6 sleets of formal Drawings (labeled as Fig. 1-Fig.4B);
A copy of the Declaration (37 C.F.R. § 1.63) and Power of Another executed by the inventors and filled in the parent application

Preliminary Amendment (3 pages);

A copy of the recorded Assignment to Astra Pharma Inc. executed by the inventors and filed in the parent application (6 pages);

A copy of the Merger document assigning rights from Astra Pharma Inc. to AstraZencea Canada Inc. filed in the parent

application (8 pages); A copy of the Assignment from AstraZeneen Canada Inc. to the No

application (4 pages); General Authorization for Pethion for Extension of Time Under C.F.R. § 1.136(a)() (General Authorization to Charge Deposit Account (1 page);

7.

B,

Information Disclosure Statement (3 pages); List of References Cited by Applicant (3 pages); and 10,

Two (2) return postcards.

PLEASE DATE STAMP AND RETURN BY COURIER

RECEIPT FROM USPTO FOR INDICATED ITEMS

Appin, No.:-

TO BE ASSIGNED

Attorney:

M. Sanzo

Filed:

HEREWITH

Date:

December 30, 2003

inventor(s):

Atty. Dkt.:

7567/80958

6.

AHMAD, ET AL.

NOVEL G PROTEIN-COUPLED RECEPTOR

WHEN RECEIPT STAMP IS PLACED HEREON, THE USPTO ACKNOWLEDGES RECEIPT OF THE FOLLOWING DOCUMENTS: OUR COVER LETTER ENCLOSING:

A copy of application no. 09/254,227, as filed in the U.S. Patent and Trademark Office on March 3, 1999, comprising: a title page naming Shen Shi-Hsinog, Sultan Ahmad, Yves Fortin, Denis Burvillo, Dajan Odounoll and Paola Lombo as inventors

62 pages of specification (numbered as pages 1-62), 5 pages of claims (numbered as pages 63-67), a one page abstract (numbered as page 68), and 6 shoots of formal Drawings (labeled as Fig. 1-Fig.4B);

A copy of the Declination (37 C.F.R. § 1.63) and Power of Attorney executed by the inventors and filed in the parent application 2. (5 pages);

Preliminary Amendment (3 pages);

A copy of the recorded Assignment to Astra Pharma (no. executed by the inventors and filed in the parent application (6 pages); A copy of the Merger document assigning rights from Astra Phanna Inc. to AstraZeneca Cunada Inc. filed in the parent

application (8 pages); A copy of the Assignment from AstruZeneca Canada Inc. to the National Research Council of Canada filed in the parent

application (4 pages);

General Authorization for Petition for Extension of Time Under 37 C.F.R. § 1.136(a)(3) (1 page); General Authorization to Charge Doposit Account (1 page);

Information Disclosure Statement (3 pages);

List of References Cited by Applicant (3 pages); and 10.

Two (2) return postcards.

00727 U.S. PTO

PLEASE HOLD FOR SERIAL NUMBER